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Abstract. BCG remains the only possible prophylactic intervention against Buruli ulcer (BU). Estimating its public
health impact on BU control is an important issue. We conducted a case-control study to investigate the vaccine
effectiveness of routine BCG vaccine against BU in southern Benin. From August 2002 to August 2003, BCG vacci-
nation status was obtained for 279 clinically diagnosed BU cases and 988 age- and sex-matched neighborhood controls.
BCG coverage, which was estimated by the presence of a scar or a vaccination record, was 64.5% in cases and 67.2%
in controls. There was no evidence of a protective effect of routine BCG vaccination against BU in southern Benin
(vaccine effectiveness adjusted for socioeconomic status  12%, 95% confidence interval  −24% to 37%).
INTRODUCTION
In 1998, Mycobacterium ulcerans disease was declared by
the World Health Organization as an emerging skin disease of
public health concern.1 Usually called Buruli ulcer (BU), the
disease has been reported in at least 30 (mostly tropical)
countries.2 The major burden is in west Africa3–5 where the
clinical lesion starts as a painless subcutaneous nodule,
plaque, or edema that secondarily ulcerates with characteris-
tic undermined edges.6 Bones can also be involved.7 Al-
though there is an increasing evidence of the efficacy of an-
tibiotic therapy, treatment still relies on surgical excision of
infected and necrotic tissues. Since BU mostly affects rural
populations with limited geographic, financial, and cultural
access to health services, patients usually present late with
severe clinical forms of the disease, including extensive skin
destruction, multiple lesions, secondary infection and/or bone
involvement. Even with adequate treatment, permanent dis-
abilities can remain.
Control strategies against BU are limited because of a lack
of knowledge of potential risk factors and the absence of a
specific vaccine. The protective effect of BCG vaccination in
preventing BU remains controversial. Two trials conducted in
Uganda8,9 reported short-lasting protection (47%), and a case
series in Benin suggested that BCG could protect against BU
osteomyelitis.10,11 Conversely, case-control studies conducted
in Ghana12,13 did not provide any evidence of a protective
effect of BCG against BU. In a recent large hospital-based
case-control study conducted in Benin, Debacker and oth-
ers14 reported an increased risk of BU after BCG vaccination
in adults and children more than five years of age. Since BCG
is the only prophylactic intervention, estimating its public
health impact on BU control is an important issue.
The frequency of BU varies widely from village to village,
even within the same district,15,16 which presumably reflects
differences in environmental exposure to M. ulcerans. Studies
of risk factors for disease must take into account this variation
in exposure. We present a case-control study with neighbor-
hood controls to assess the effectiveness of routine BCG vac-
cination in preventing BU in southern Benin.
METHODS
Setting. The study was conducted in southern Benin. Buruli
ulcer is endemic in this area with more than 5,700 patients
reported since 1989.2 In 2002, the area included two reference
centers for the treatment of BU: the Center Sanitaire et Nu-
tritionnel Gbemoten (CSNG) at Zagnanado, Zou region, and
the Center de Dépistage et de Traitement de l’Ulcère de
Buruli (CDT/UB) at Lalo, Mono-Couffo region. Patients
come directly to these centers, often motivated by previously
treated patients, and are also referred through village out-
reach activities.4 In 2003, the prevalence of human immuno-
deficiency virus among Beninese adults 15–49 years of age
was estimated to be between 1.1% and 3.3%.17
Since the implementation of the Beninese Expanded Pro-
gram of Immunization (EPI) in 1982, the vaccination policy is
to administer BCG at birth. BCG had always been adminis-
tered intradermally on the upper third of the dorsal surface of
the left forearm. It was not possible to obtain information on
the strains and doses used in Benin but it is likely that they
varied over time.
Cases. From August 2002 to May 2003 at the CSNG and
from August 2002 to August 2003 at the CDT/UB, all patients
clinically diagnosed with BU by medical officers specialized in
BU treatment were eligible for enrollment. Patients living
outside Benin were excluded, as were those living in the cities
of Cotonou and Porto-Novo, because it is unlikely that they
contracted BU in those urban areas.
Controls. The study protocol aimed to recruit four controls
per case. Neighborhood controls were individually matched
to cases by sex and age (categories: < 1, 1–5, 6–12, 13–19,
20–29, 30–39, and  40 years). A door-to-door systematic
procedure was used for control selection. Field investigators
started at the case’s house, chose a random direction, and
visited the nearest house. They listed all members of the
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household and identified potential controls fitting the match-
ing criteria. If several subjects were identified, they chose the
closest in age to the case. The procedure was repeated in each
consecutive house until four appropriate controls were found.
If identified potential controls were absent, one or two addi-
tional visits were planned. Controls were examined to rule
out active or healed BU.
Data collection. Clinical information was abstracted from
medical records. Lesions were classified according to clinical
form: nodule, plaque, edema, ulcer, osteomyelitis, mixed, and
other lesions. Specimens of tissue and of exudates from some
patients were analyzed by Ziehl-Neelsen staining, culture,
IS2404 polymerase chain reaction, and histopathologic exami-
nation18 to confirm the clinical diagnosis. Participants were
examined for a BCG scar. When available, vaccination
records were checked. All subjects were asked about prior
BCG vaccination. For children less than 15 years of age, par-
ents or guardians were used as informants. Evidence of BCG
vaccination was defined by a BCG scar or a BCG vaccination
record. Individuals with a doubtful scar were excluded from
the analysis. In a separate analysis, we also excluded subjects
without a scar or vaccination record but who provided a his-
tory of BCG vaccination. Scar size was not recorded.
Participants or guardians answered a questionnaire. Ques-
tions on socioeconomic characteristics included education
level of the participants, education level and occupation of
the head of the participant’s household, type of house, and
possession of selected items by the household (radio, bicycle,
motorbike, car, and dugout canoe). The household was de-
fined as all subjects sharing the same roof and the same cook-
ing pot. Factors recorded to estimate likely environmental
exposure to M. ulcerans included participation in farming,
water-contact frequency with distinction between stagnant
and flowing water, and main drinking water source and draw-
ing water at this source. Information on whether young chil-
dren accompanied adults during farming or obtaining water
was recorded.
Interviews were conducted in French, Fon, or Adja by
nurses or biomedical technicians trained in the study proto-
col, BCG scar reading and recognizing BU lesions. Hospital
and field teams included different investigators not blind to
the disease status of the participants.
Statistical analysis. Estimating from a preliminary pilot
study that 25% of the controls and 35% of the cases had no
BCG scar, the proportion of discordant pairs was expected to
be 43%. To have 80% power to detect whether the odds ratio
(OR) is significantly different from 1 at the 5% level, with a
VE of 40% considered to be clinically relevant, the sample
should include 208 cases and 832 matched-controls in a 1:4
matched ratio.19 In practice, we aimed to recruit 300 cases to
allow subgroup analysis.
The ORs and 95% confidence intervals (CIs) were calcu-
lated using conditional logistic regression. Associations were
tested using the likelihood ratio test (LRT) and, for ordered
categorical variables, the LRT for trend. Vaccine effective-
ness (VE%) was calculated as (1 − OR) × 100.20 Estimation
of VE was adjusted for socioeconomic status (SES) and for
factors estimating likely environmental exposure to M. ulcer-
ans; age, sex, and neighborhood were accounted for by the
matched design and analysis. The SES was measured by
house type, education level of the head of the household, and
a score of ownership based on household possession of a
radio, bicycle, motorbike, dugout canoe, or car. Items were
weighted according to the inverse frequency of households
owning this item in rural Benin in 200121 and then summed.
Higher scores therefore reflected both greater ownership and
owning less common (and by inference more valuable) items.
Vaccine effectiveness was assessed separately for age groups
older and younger than 20 years (born after the implementa-
tion of the EPI and therefore likely to have been vaccinated
at birth), by sex, for laboratory confirmed BU, and for pa-
tients with BU osteomyelitis. Differences between subgroups
were tested for interaction using LRT. Reliability of scar
reading was estimated using a kappa coefficient for multiple
observers. Data were entered in Epi-Info version 6.04 (Cen-
ters for Disease Control and Prevention, Atlanta, GA) and
analyzed with STATA version 9.0 (Stata Corporation, Col-
lege Station, TX).
Ethics. Data were collected after informed consent of the
participant or participant’s guardian. Potential controls with
BU lesions were offered appropriate treatment. The study
was reviewed and approved by the Beninese Public Health
Minister.
RESULTS
Study population. Among the 446 eligible patients, 2 re-
fused participation in the study, 3 were excluded because of
doubtful scars, 1 was excluded because of missing BCG data,
42 were excluded because a BU lesion on the left forearm
made identification of a BCG scar impossible, and 78 (17.5%)
were not recruited because of work overload in the health
centers. Information on BCG status was thus available for 320
patients. Mainly because of wrongly listed addresses and im-
passable roads preventing field teams from reaching villages,
suitable controls could be matched for only 229 (71.6%) of
these patients. Fifty patients hospitalized for BU at the CSNG
between January and August 2002 and living in villages vis-
TABLE 1
Description of the cases (n  279) of Buruli ulcer in Benin
Variable No. %
Clinical form†
Edema 8 2.9
Ulcer 127 45.7
Nodule 7 2.5
Plaque 61 21.9
Osteomyelitis 7 2.5
Others 3 1.1
Mixed 65 23.4
Clinical stage†
Not ulcerative 92 33.1
Ulcerative 137 49.3
Healing 34 12.2
Several stages 12 4.3
Others 3 1.1
Number of positive laboratory test results‡
0 45 16.1
1 34 12.2
 2 100 35.8
Untested 100 35.8
Hospitalized at the CDT/UB, Lalo* 92 33.0
Hospitalized at the CSNG, Zagnanado* 187 67.0
* CDT/UB  Centre de Dépistage et de Traitement de l’Ulcère de Buruli; CSNG 
Centre Sanitaire et Nutritionnel Gbemoten.
† One missing value.
‡ Ziehl-Neelsen staining, histology, culture and/or polymerase chain reaction.
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ited by the field investigators were retrospectively recruited
with suitable controls. They were included in the analysis,
resulting in a total of 279 matched sets. Cases included in the
matched analysis were similar to the eligible cases not in-
cluded regarding sex and age, but they were more likely to
have come from the Ouémé region and to be vaccinated with
BCG (64.5% versus 50.5%; P  0.018).
In 7 of more than 200 villages visited, local authorities re-
fused to allow persons to participate in the study. Eight con-
trols were reported to have refused to answer the question-
naire but individual refusals were not systematically recorded.
Three controls with suspected BU lesions, 3 with missing
BCG data, and 25 with doubtful scars were excluded. A total
of 988 controls were matched to the 279 cases (average
matching ratio  1:3.5).
Clinical description of cases. The median age was 13.4 years
(range 11 months to 80 years) and 47% were female. Ulcer
was the most frequent form (46%) followed by the mixed
(23%) and the plaque forms (22%) (Table 1). A total of 24
(8.7%) patients had bone involvement (7 without active skin
lesions and 17 with a mixed form of BU). Recurrence ac-
counted for 21 (7.5%) of the cases. Forty-eight percent of the
cases were confirmed by at least one of the four laboratory
tests (Table 1).
Sociodemographic characteristics and SES. Matching re-
sulted in sex, age, and region of residence being similar in
cases and controls (Table 2). The predominant ethnic group
was Fon. Cases were more likely than controls to live in
cemented or brick houses and were of higher SES as mea-
sured by the score of ownership and education level of
the head of the household (Table 3). However, there was
no evidence that education level of cases and controls more
than 20 years of age differed (Table 3). Among those
6–19 years of age, 83 (61.9%) of the cases were currently
attending school compared with 306 (66.0%) of the controls
(P  0.38).
BCG vaccination coverage. BCG coverage estimated by
the presence of a scar or a vaccination record was 64.5%
among 279 cases and 67.2% among 988 controls. As shown in
Table 4, 11 participants with a scar or a BCG vaccination
record claimed not to have been vaccinated. Thirty (30.3%)
of 99 cases and 117 (36.1%) of 323 controls without a scar or
vaccination record claimed to have been vaccinated. Overall,
TABLE 2
Demographic characteristics of the participants
Cases
No. (%)
n  279
Controls
No. (%)
n  988 P
Female 131 (47.0) 467 (47.3) *
Age (years) *
< 6 36 (12.9) 114 (11.5)
6 to < 13 99 (35.5) 360 (36.4)
13 to < 20 36 (12.9) 136 (13.8)
20 to < 30 39 (14.0) 133 (13.5)
30 to < 40 18 (6.5) 72 (7.3)
 40 51 (18.3) 173 (17.5)
Region of residence *
Atlantique 14 (5.0) 43 (4.4)
Ouémé-Plateau 122 (43.7) 429 (43.4)
Zou 52 (18.6) 179 (18.1)
Mono-Couffo 91 (32.6) 337 (34.1)
Ethnicity† 0.43‡
Fon 222 (80.1) 792 (80.7)
Adja 48 (17.3) 169 (17.2)
Others 7 (2.5) 21 (2.1)
* Matching variable.
† Two matched sets lost due to missing data in cases.
‡ By conditional logistic regression.
TABLE 3
Socioeconomic characteristics of the participants
Cases
No. (%)
Controls
No. (%) OR (95%CI)* P†
House type < 0.001
Mud, wood, straw 75 (27.3) 369 (38.5) 1
Mud, sheet metal roof 139 (50.6) 538 (56.2) 1.49 (1.03, 2.14)
Cement, brick 61 (22.2) 51 (5.3) 10.04 (5.64, 17.84)
Head of the household’s education level 0.006‡
None 149 (56.9) 581 (64.3) 1
Primary uncompleted 59 (22.5) 190 (21.0) 1.30 (0.81, 1.83)
Completed primary or higher 54 (20.6) 132 (14.6) 1.77 (1.19, 2.59)
Participant’s education level (> 20 years) 0.43
None 72 (67.9) 273 (73.8) 1
Primary uncompleted 20 (18.9) 55 (14.9) 1.51 (0.79, 2.91)
Completed primary or higher 14 (13.2) 42 (11.4) 1.44 (0.62, 3.34)
Head of the household’s occupation 0.028
Farmer, fisher 167 (61.9) 661 (70.8) 1
Manual, trade, driver 63 (23.3) 189 (20.2) 1.35 (0.93, 1.96)
Professional 24 (8.9) 53 (5.7) 2.02 (1.13, 3.64)
Village/religious authority, traditional healer 6 (2.2) 17 (1.8) 1.53 (0.56, 4.13)
Retired, none 10 (3.7) 14 (1.5) 3.15 (1.16, 8.54)
Score of ownership§ < 0.001‡
1 28 (10.4) 159 (17.1) 1
2 91 (33.7) 400 (42.9) 1.40 (0.85, 2.30)
3 101 (37.4) 287 (30.8) 2.20 (1.33, 3.64)
4 50 (18.5) 86 (9.2) 4.36 (2.40, 7.95)
* OR  odds ratio; CI  confidence interval.
† By conditional logistic regression.
‡ By conditional logistic regression. Test for trend.
§ Household possession of a radio, bicycle, motorbike, dugout or car; items were weighted according to the inverse frequency of households owning this item in rural Benin in 200121 and then
summed and categorized.
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84.0% of the 920 participants claiming to have been vacci-
nated with BCG had a recognizable scar or a BCG vaccina-
tion record.
Sixty-two subjects (16 cases and 46 controls) had a BCG
vaccination record. They were less than 12 years of age and
were vaccinated before five months of age. Scar examination
in two of them was not possible because the BU lesion was on
the vaccination site; 13.3% (8 of 60) had no scar.
A subsample of subjects were examined independently for
BCG scar by four investigators of CSNG (n 53) and three
investigators of CDT/UB (n  27). Kappa coefficients were
0.78 for CSNG and 0.90 for CDT/UB, which indicated good
intra-observer agreement on the presence of a scar.
BCG vaccine effectiveness. The BCG VE was 15% (95%
CI −15% to 37%, P 0.29) (Table 5). When adjusted for
SES, as measured by education level of the head of the house-
hold, score of ownership and type of house, VE changed very
little (Table 5). Adjusting for head of the household’s occu-
pation or for the participant’s education level did not change
the estimates. The estimates were also unchanged after addi-
tionally adjusting for factors measuring likely environmental
exposure to M. ulcerans (contacts with flowing water, contacts
with stagnant water, participation in farming, and drawing
surface water for drinking).
Few participants had more than one BCG scar and the
trend for an increased VE with increasing number of doses
was not statistically significant (Table 5). Excluding subjects
without scar or vaccination record but reporting a history of
BCG vaccination increased the VE estimations (Table 5) but
still provided weak evidence for a protective effect of BCG
against BU.
Table 6 shows VE estimations for patient subgroups. The
VE was higher in subjects more than 20 years of age but CIs
were wide, and the test for interaction did not provide evi-
dence for a true difference compared with VE in younger
people. Also, the VE was higher in females than in males, but
the interaction was not statistically significant. The VE was
similar in laboratory-confirmed cases and unconfirmed cases.
The VE tended to be higher against BU osteomyelitis com-
pared with other forms of BU, but there was no statistical
evidence for a difference, as reflected by the overlapping
95% CIs.
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TABLE 4
BCG vaccination status of cases and controls according to the source
of information
Clinical examination for a BCG scan
and BCG vaccination record
History of BCG vaccination
according to the subject
or subject’s guardian*
Yes No
Do not
know Total
Cases
Presence of a BCG scar 148 4 12 164
BCG vaccination record (± BCG scar) 15 1 0 16
Not BCG vaccinated (no scar, no record) 30 59 10 99
Total 193 64 22 279
Controls
Presence of a BCG scar 567 6 44 617
BCG vaccination record (± BCG scar) 43 0 3 46
Not BCG vaccinated (no scar, no record) 117 158 48 323
Total 727 164 95 986
* Missing value in one control with a BCG scar and one control without BCG scar or BCG
vaccination record.
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DISCUSSION
Our study does not provide evidence that BCG adminis-
tered under routine conditions in Benin reduces the risk of
BU among those vaccinated. Overall VE estimation adjusted
for SES was 12% (95% CI −24% to 37%). Although the CI
is wide, strong protection is unlikely.
Our results are consistent with those of two case-control
studies conducted in Ghana.12,13 Those studies were designed
to investigate several potential risk factors for BU, including
presence of a BCG scar. Although the investigators did not
report the OR (or VE), they reported no statistically signifi-
cant difference in BCG scar prevalence between cases and
matched neighborhood controls of similar age, as in our
study.
In two Ugandan trials,8,9 VE against BU was estimated to
be 72% in the first 6 months8 and 63% in the first year9 after
vaccination; it then waned to 0%. BCG was administered to
subjects (from less than one to more than 25 years of age)
with weak or negative tuberculin reactions. Besides important
differences in geographic location and design, our results are
difficult to compare with those trials because most of our
participants received neonatal BCG and were included in the
study more than one year after vaccination. Also, those stud-
ies estimated vaccine efficacy under ideal storage, handling,
and administration conditions of a clinical trial, while our
study estimated vaccine effectiveness, i.e., efficacy under field
conditions.22
Because of the small area variation in the distribution of M.
ulcerans15,16 and the likely geographic variation of BCG vac-
cine coverage, we used neighborhood controls. We were able
to adjust for factors linked to likely environmental exposure
to M. ulcerans, and this did not change our estimates. Neigh-
borhood controls have the disadvantage of possibly being less
frequent users of health services. At the time of our study, the
CSNG and CDT/UB were the main referral centers for treat-
ing BU in southern Benin. Both centers had important village
outreach activities and some patients were referred to the
centers through active case detection. Consequently, referral
patterns of BU patients differed from those of patients
treated for other diseases in the same centers. However, as-
certainment of BU cases in the region is unlikely to have been
complete because people are often reluctant to seek medical
treatment of BU,23 mainly because of fear of surgery and the
cost of treatment, especially the indirect costs during the long
duration of hospitalization.24 We adjusted VE for SES to
minimize this bias in likely health service usage patterns be-
tween cases and controls and VE changed very little. How-
ever, SES is difficult to measure and we cannot exclude re-
sidual confounding.
Because of work overload in the health centers, not all
eligible patients were recruited, but this was regardless of
their BCG status. For those recruited, matching was incom-
plete mainly because of wrongly listed addresses and impass-
able roads that prevented field teams from reaching villages.
Included cases had a similar age and sex distribution com-
pared with those not included, but included cases came from
different geographic areas than case not included. In particu-
lar, included cases were more likely to come from the Ouémé-
Plateau region where the highest BCG coverage has been
reported.21 Also, BCG coverage is likely to be lower in dif-
ficult to reach areas. Consequently, 64.5% of the cases in-
cluded in the matched analysis were vaccinated compared
with 50.5% of those not included. Since controls were
matched in neighborhoods, this would not have biased our
VE estimation.
Only half of the cases were laboratory confirmed and mis-
classified cases can decrease VE estimation.25 However, there
was no statistical evidence for a difference in BCG VE be-
tween laboratory confirmed cases and other cases.
Uncertainty about BCG vaccination status could have led
to underestimation of BCG VE in our study. Vaccination
records were seldom available and our definition of BCG
vaccination status relied mainly on the presence of a BCG
scar. Presence of a scar is recognized as a highly sensitive and
reliable indicator of BCG vaccination status26 except when
administered within one month of birth.27 Neonatal vaccina-
tion is a long-established policy in Benin, and we could esti-
mate in our study that approximately 87% of the BCG vac-
cinations resulted in a scar. Since scar formation is probably
independent of immune response,27 this could have led to
non-differential misclassification and VE underestimation.
Therefore, we excluded subjects without BCG scars or vacci-
nation records but who claimed to have received BCG and
re-estimated BCG VE. Vaccine effectiveness estimates in-
TABLE 6
BCG vaccine effectiveness (VE) against Buruli ulcer (BU) by age group and sex for confirmed BU and BU osteomyelitis
Cases
No. (% vaccinated)†
Controls
No. (% vaccinated)†
VE (%) from matched
analysis (95% CI)*
Adjusted‡ VE (%)
(95% CI)*
Age, yearsa
< 20 171 (71.4) 610 (72.1) 7 (−37, 38) −7 (−67, 32)
 20 108 (53.7) 378 (59.3) 24 (−21, 53) 33 (−15, 60)
Sexb
Female 131 (58.8) 467 (66.4) 33 (−3, 57) 29 (−18, 57)
Male 148 (69.6) 521 (68.0) −6 (−62, 30) −6 (−67, 34)
Confirmed BU§ 134 (67.9) 465 (71.6) 21 (−25, 50) 14 (−45, 49)
Not confirmed BU 145 (61.4) 523 (63.3) 10 (−33, 40) 10 (−42, 42)
BU osteomyelitis 24 (50.0) 78 (64.1) 48 (−48, 81) 53 (−34, 83)
Other BU 253 (66.0) 902 (67.7) 12 (−21, 36) 6 (−36, 35)
* CI  confidence interval.
a P values (conditional logistic regression) for modification of VE according to age groups  0.52 (matched analysis) and 0.19 (adjusted for socioeconomic status [SES]).
b P values (conditional logistic regression) for modification of VE according to sex  0.13 (matched analysis) and 0.26 (adjusted for SES).
† Vaccinated  scar and/or vaccination record; unvaccinated  no scar and no vaccination record.
‡ Adjusted for SES: head of the household’s education level, score of ownership, and type of house.
§ Confirmed by at least one laboratory test (Ziehl-Neelsen staining, culture and IS2404 polymerase chain reaction and histopathologic examination).
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creased to 33% (SES-adjusted) but the CI was wide and still
provided weak statistical evidence for an effect of BCG in
preventing BU in Benin.
Cases and controls were examined by different investiga-
tors. They were not blinded to the disease status of the par-
ticipant or to the research hypothesis. Therefore, we cannot
formally exclude differential observer bias. However, in both
centers, teams were trained by the same member of the re-
search team, and we have no reasons to believe that cases
were more carefully examined for scars than controls.
The benefit of BCG revaccination had been reported
against leprosy, in a setting where the initial dose appeared
protective,28 but not against tuberculosis.28,29 In Uganda,
there was no evidence for an enhanced protection of BCG
revaccination against BU.9 We observed a trend for an in-
creased VE in subjects with more than one scar attributable
to BCG vaccination. However, few subjects had more than
one scar and the trend was not statistically significant. We also
found a higher protective effect of BCG against BU osteo-
myelitis, which is consistent with the observations of Portaels
and others,10,11 but the numbers of patients were small.
We found higher VE for subjects more than 20 years of age
compared with younger persons. This is surprising because
VE is expected to wane with time since vaccination,30 and VE
estimation in subjects more than 20 years of age measured the
long-lasting protection conferred by BCG administered at
least 20 years previously. Underestimation of VE could be
serious if less than 90% of the vaccinations left a scar and
more than 70% of the population has been vaccinated,31
which is the case for subjects younger than 20 years of age
included in our study. This underestimation could therefore
have been more important in this group than in the older age
group, in whom vaccination coverage was less than 60% and
vaccines may have been given beyond the neonatal period.
However, there was no statistical evidence for a true differ-
ence of BCG VE between age groups.
Although our BCG VE estimations could have been
slightly underestimated, our data do not provide evidence of
a strong protective effect of routinely administered BCG
against BU in southern Benin. From a public health perspec-
tive, routine neonatal BCG appears of little value in control-
ling BU in this population. Thus, effective prevention of BU
by immunoprophylaxis needs further vaccine development.
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